Journal ArticleDOI
Progesterone receptors as a prognostic factor in Stage II breast cancer.
TLDR
Examining both receptors along with other risk factors in 189 patients receiving adjuvant therapy for Stage II breast cancer suggests that determination of the progesterone-receptor concentration is of equal or greater value than determination of that of estrogen receptors.Abstract:
The presence of estrogen receptors in breast cancers is now accepted as a predictor of extended disease-free survival, but the relative value of progesterone receptors for this purpose has not been established. We have examined both receptors along with other risk factors in 189 patients receiving adjuvant therapy for Stage II breast cancer. The presence of either estrogen receptors or progesterone receptors was positively correlated with disease-free survival when analyzed separately, whether or not the adjuvant regimen included an endocrine component. However, when estrogen receptors and progesterone receptors were analyzed together in multivariate models, the presence of progesterone receptors was more significant than that of estrogen receptors for predicting time to recurrence, regardless of what other variables were included in the model. These data suggest that determination of the progesterone-receptor concentration is of equal or greater value than determination of the estrogen-receptor ...read more
Citations
More filters
Journal ArticleDOI
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Dennis J. Slamon,Gary M. Clark,Steven G. Wong,Wendy J. Levin,Axel Ullrich,William L. McGuire +5 more
TL;DR: Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer, and had greater prognostic value than most currently used prognostic factors in lymph node-positive disease.
Journal ArticleDOI
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond,Daniel F. Hayes,Mitch Dowsett,D. Craig Allred,Karen L. Hagerty,Sunil V. Badve,Patrick L. Fitzgibbons,Glenn Francis,Neil S. Goldstein,Malcolm Hayes,David G. Hicks,Susan C. Lester,Richard Love,Pamela B. Mangu,Lisa M. McShane,Keith Miller,C. Kent Osborne,Soonmyung Paik,Jane Perlmutter,Anthony Rhodes,Hironobu Sasano,Jared N. Schwartz,Fred C.G.J. Sweep,Sheila E. Taube,Emina Torlakovic,Paul N. Valenstein,Giuseppe Viale,Daniel W. Visscher,Thomas M. Wheeler,R. Bruce Williams,James L. Wittliff,Antonio C. Wolff +31 more
TL;DR: An international Expert Panel that conducted a systematic review and evaluation of the literature and developed recommendations for optimal IHC ER/PgR testing performance recommended that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences.
Journal ArticleDOI
Biological determinants of endocrine resistance in breast cancer
TL;DR: The development of large-scale computational and genetic approaches offers the promise of identifying the mediators of endocrine resistance that may be exploited as potential therapeutic targets and biomarkers of response in the clinic.
Journal ArticleDOI
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial
Matthew J. Ellis,Andrew Coop,Baljit Singh,Louis Mauriac,Antonio Llombert-Cussac,Fritz Jänicke,William R. Miller,Dean B. Evans,Margaret Dugan,Carolyn Brady,Erhard Quebe-Fehling,Mieke Borgs +11 more
TL;DR: It is suggested that ErbB-1 and Erb B-2 signaling through ER is ligand-dependent and that the growth-promoting effects of these receptor tyrosine kinases on ER+ breast cancer can be inhibited by potent estrogen deprivation therapy.
Journal ArticleDOI
Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization
Jan Budczies,Frederick Klauschen,Bruno Valentin Sinn,Balázs Győrffy,Wolfgang D. Schmitt,Silvia Darb-Esfahani,Carsten Denkert +6 more
TL;DR: The functionality of Cutoff Finder is illustrated by the analysis of the gene expression of estrogen receptor and progesterone receptor in breast cancer tissues, which is analyzed and correlated with immunohistologically determined ER status and distant metastasis free survival.
References
More filters
Journal ArticleDOI
The Statistical Analysis of Failure Time Data.
Journal ArticleDOI
The statistical analysis of failure time data
TL;DR: In this article, the authors proposed a regression model for failure time distributions in the context of counting process models and showed that the model can be used to estimate the probability of failure.
Journal ArticleDOI
Covariance analysis of censored survival data.
TL;DR: The use of regression models for making covariance adjustments in the comparsion of survival curves is illustrated by application to a clinical trial of maintenance therapy for childhood leukemia.
Journal Article
Estrogen Receptor as an Independent Prognostic Factor for Early Recurrence in Breast Cancer
William A. Knight,William A. Knight,Robert B. Livingston,Ernest J. Gregory,William L. McGuire +4 more
TL;DR: The usefulness of estrogen receptor measurements in primary breast tumors in the prediction of early recurrence was examined in a series of 145 patients and the absence of estrogenceptor in such tumors was associated withEarly recurrence independent of other known prognostic factors.
Related Papers (5)
The value of estrogen and progesterone receptors in the treatment of breast cancer
Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.
H. J. G. Bloom,W. W. Richardson +1 more